A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)

NCT06326671 | Active Not Recruiting Phase 1

• 1 other identifier: STXA-BE-03
• Study Type: interventional
• Target: 39
• Locations: 1 country
• Sites: 1

Brief Summary

Primary Objective: To evaluate the pharmacokinetics of Tiotropium Bromide Inhalation Powder (Strength:18 mcg; manufactured by Chia Tai Tianqing Pharmaceutical Group Co. Ltd) and reference products Tiotropium Bromide Inhalation Powder (Spiriva®, Handihaler®, Strength: 18mcg, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc) by oral inhalation of single dose in healthy participants under fasting conditions.

Conditions

Chronic Obstructive Pulmonary Disease

Outcome Measures

Primary Outcomes (3)

• Peak concentration (Cmax)

  Maximum plasma drug concentration

  Pre-dose and 1 2, 3, 4, 5 6, 7, 8, 10, 15, 20, 30 minutes, 1, 2, 4, 8, 12, 24, 48, 72, 120, 168, 216 hours post-dose

• Area under the plasma concentration versus time curve (AUC) 0-t

  plasma concentration-time curve from zero to the time of the last measurable time point t.

  Pre-dose and 1 2, 3, 4, 5 6, 7, 8, 10, 15, 20, 30 minutes, 1, 2, 4, 8, 12, 24, 48, 72, 120, 168, 216 hours post-dose

• Area under the plasma concentration versus time curve (AUC) 0-∞

  area under the plasma concentration-time curve from zero to infinity

  Pre-dose and 1 2, 3, 4, 5 6, 7, 8, 10, 15, 20, 30 minutes, 1, 2, 4, 8, 12, 24, 48, 72, 120, 168, 216 hours post-dose

Secondary Outcomes (3)

• The time to maximum plasma concentration (Tmax)

  Pre-dose and 1 2, 3, 4, 5 6, 7, 8, 10, 15, 20, 30 minutes, 1, 2, 4, 8, 12, 24, 48, 72, 120, 168, 216 hours post-dose

• The elimination half-life (t1/2)

  Pre-dose and 1 2, 3, 4, 5 6, 7, 8, 10, 15, 20, 30 minutes, 1, 2, 4, 8, 12, 24, 48, 72, 120, 168, 216 hours post-dose

• Terminal elimination rate constant (Kel)

  Pre-dose and 1 2, 3, 4, 5 6, 7, 8, 10, 15, 20, 30 minutes, 1, 2, 4, 8, 12, 24, 48, 72, 120, 168, 216 hours post-dose

Study Arms (2)

Test Product Tiotropium Bromide Inhalation Powder (Strength: 18 mcg)

EXPERIMENTAL

The subjects randomly received single oral inhalation dose of Tiotropium bromide inhaling powder generic product.

Drug: Tiotropium Bromide Inhalation Powder

Reference Product (Spiriva®Handihaler®, Strength: 18 mcg)

ACTIVE COMPARATOR

The subjects randomly received single oral inhalation dose of the reference listed drug (RLD) Spiriva®Handihaler®.

Drug: Spiriva HandiHaler

Interventions

Tiotropium Bromide Inhalation Powder DRUG

It's a generic product of Spiriva HandiHaler.

Test Product Tiotropium Bromide Inhalation Powder (Strength: 18 mcg)

Spiriva HandiHaler DRUG

Tiotropium Bromide Inhalation Powder RLD, which binds to M3 receptors, and blocks the action of acetylcholine to relieve spasm of bronchial smooth muscle.

Reference Product (Spiriva®Handihaler®, Strength: 18 mcg)

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Able to give signed Informed Consent Form before the trial, and fully understand the trial content, process and possible adverse drug reactions (ADRs);
• Able to complete the trial in compliance with the protocol;
• Participants (including males) willing to adopt effective contraceptive methods and with no pregnancy plan from 14 days before screening to 3 months after the last scheduled visit;
• Males and females between 18 and 55 years old (included);
• At least 50 kg for males, 45 kg for females, with a Body Mass Index (BMI) = Weight/Height2 (kg/m2) between 19.0-26.0 kg/m2 (included);
• No history of cardiac, hepatic, renal, ophthalmology and otorhinolaryngology, respiratory system, urogenital system, digestive tract, nervous system, mental and metabolic disorders, etc.

You may not qualify if:

• Take ≥ 5 cigarettes per day on average within 3 months before screening, or not able to quit smoking during the trial, or urine nicotine test is positive;
• Be allergic to tiotropium, atropine or its derivatives (e.g., ipratropium, oxitropium) or any excipient of tiotropium bromide inhalation sprays; or allergic constitution (be allergic to two or more drugs, food and pollen allergy); or with specific allergy history (asthma, urticaria, eczema, etc.);
• A history of alcohol abuse (alcohol consumption of more than 14 units per week: 1 unit of alcohol = 285 mL beer, or 25 mL spirits, or 100 mL wine);
• Blood donation or massive blood loss (≥ 400 mL) within 3 months before the initial administration; Or any blood donation plan from screening until 1 month after the last administration;
• Participants who have an acute upper respiratory tract infection within 2 weeks prior to receiving investigational product;
• History of any clinically significant diseases or any other diseases that could interfere with the study results. Including but not limited to the circulatory system, gastrointestinal system, urinary system (such as history of prostate hypertrophy, bladder neck obstruction, uroschesis, etc.), respiratory system (such as acute onset of chronic obstructive pulmonary disease, pulmonary fibrosis, pulmonary hypertension, pulmonary edema, pulmonary interstitial disease, bronchospastic pulmonary disease, bronchial asthma, etc.), ophthalmology (such as: glaucoma, etc.), nervous system, immune system, endocrine system, malignant tumor, mental and metabolic abnormalities; or with history of nasopharyngitis, throat ulcers, edema, or history of throat, tracheal/bronchial and lung surgery in the past;
• History of sicca syndrome or habitual constipation;
• Function test: the forced expiratory volume in one second measured value / the forced expiratory volume in one second predicted value ≤80% or the forced expiratory volume in one second / forced vital capacity ≤80%;
• Any prescription medication within 14 days before the initial administration;
• Any over-the-counter (OTC) medication or Chinese herbal medicine or health supplementary within 7 days before the initial administration;
• Consumption of any special diets (such as grapefruit), or strenuous exercise engagement, or other factors affecting drug absorption, distribution, metabolism and excretion within 7 days before the initial administration;
• Participation in other drug clinical trials within 3 months before the initial administration;
• Any clinically significant abnormality findings, as judged by a clinical physician, such as physical examination, vital signs, electrocardiogram, chest X-ray examination and laboratory tests;
• Positive results of hepatitis B surface antigen, hepatitis C antibody, and HIV antibody or syphilis;
• Consumption of chocolate or any food/beverage containing caffeine or rich in xanthine within 48 hours before the initial administration;

Sponsors & Collaborators

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.: lead

Study Sites (1)

Henan (Zhengzhou) Zhonghui Cardiovascular Hospital

Zhengzhou, Henan, 450003, China

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 17, 2024
• First Posted: March 22, 2024
• Study Start: February 28, 2024
• Primary Completion: March 1, 2024
• Study Completion: April 1, 2024
• Last Updated: March 29, 2024

Record last verified: 2024-03

Locations

CN (1)